Media ReleasesImpediMed

View All ImpediMed News

ImpediMed - Appendix 4C & Quarterly Activities Report

Robust results

-- Robust quarter despite meaningful impact from Omicron variant
-- Record results in Q2 FY’22 for SOZO®SaaS revenue
-- $50.8m cash balance and fully funded to cashflow break-even post capital raising


-- PREVENT Trial peer-reviewed, accepted and pending publication in coming days
-- Met primary end point
-- Statistically significant
-- Showed statistical benefit across all risk factors

Foundation laid for accelerated growth

-- Rapidly expanding our Case Assistance Program (CAP) due to its overwhelming success
-- CAP will be strengthened by PREVENT Trial publication
-- Principal Investigators to submit NCCNapplication in the coming week
-- Measured expansion of customer facing resources as we accelerate growth

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.